These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000593-32 A 6-week open label cross-over study with 2 different daily doses of Minirin oral lyophilisate (120 µg and 240 µg) and 2 different daily doses of Minirin tablet (0.2 mg and 2 x 0.2 mg) in children and... 2005-09-12 due-trials
Reported results 2004-001307-35 A prospective, open label, randomised, parallel group, comparative pilot study to study the efficacy and safety of highly purified Menotrophin versus recombinant FSH (Follitropin alfa) administered su... 2009-05-12 due-trials
Ongoing 2004-001735-37 AN OPEN LABEL STUDY OF ORAL DESMOPRESSIN IN CHILDREN AGED 5 TO 15 YEARS WITH PRIMARY NOCTURAL ENURESIS not-yet-due
Reported results 2004-002802-31 Multicentre, Controlled, Randomised, Open, Cross-over Study Comparing the Acceptability of Pentasa® Sachets versus Pentasa® tbl. 500mg in Children with Crohn´s Disease 2006-02-10 due-trials
Reported results 2004-003814-40 An open-label, multi-centre, extension study evaluation the long-term safety and tolerability of Degarelix one-month depots in patients with prostate cancer 2009-10-13 due-trials
Reported results 2004-003815-22 An Open-Label, Multi-Centre, Randomised Parallel Group Comparison of Efficacy and Safety of Degarelix Three-Month Depot in Three Different Dosing Regimens of 240 mg (40 mg/mL) and 240 mg (60 mg/mL) in... 2006-11-08 due-trials
Reported results 2004-004565-15 Pentasa® Once Daily In Ulcerative colitis for Maintenance of remission: PODIUM An International multi-centre investigator blinded randomised controlled study of Pentasa ® Sachet comparing one gram t... 2007-06-15 due-trials
Reported results 2005-001539-31 An Open-label, Multi-centre, Phase III Study of Local Tolerability of Zomacton 10 mg (Recombinant Somatropin) administered by ZomaJet Vision X 2006-11-10 due-trials
Reported results Terminated 2005-002472-15 The effect on mucosal healing with Pentasa® Sachet 4 g in mild to moderate active small bowel Crohn's disease, evaluated with video capsule endoscopy after 6 and 12 weeks treatment. A pilot study. 2009-07-31 due-trials
Completed, but no date, and reported results 2005-002531-27 The PEACE Study: Investigating the Pharmacodynamics and Pharmacokinetics of FE 106483 Tablets in a Single Dose Study in Children with Nocturnal Enuresis. A Randomised, Double-Blind and Placebo-Control... bad-data
Reported results 2005-004943-72 An Open-Label, Multi-Centre, Extension Study, evaluating the Long-Term Safety and Tolerability of Different Three-Month Degarelix Dosing Regimens in Patients with Prostate Cancer. 2009-09-16 due-trials
Reported results 2005-005595-33 An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUP... 2007-10-08 due-trials
Reported results 2006-000415-15 EQUIPO (Efecto de Quinagolida en la Prevención de OHSS) Estudio de prueba de hipótesis, aleatorizado, doble ciego, de grupos paralelos, en búsqueda de dosis, controlado con placebo, multicéntrico, pa... 2007-08-11 due-trials
Reported results 2006-004684-58 A randomised, assessor-blind, parallel groups, multi-centre, exploratory study assessing the impact of subcutaneous administration of degarelix 2.5 mg on synchronisation of follicle cohort compared to... 2008-08-27 due-trials
Reported results 2006-006913-34 An Open-Label, Multi-Centre, Extension Study, Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Patients with Prostate Cancer Requiring Androgen Ablation Therap... 2011-10-20 due-trials
Reported results 2007-001650-77 An Open-Label, Multi-Centre, Randomised Parallel-Group Dose-Finding Study, Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring And... 2008-08-18 due-trials
Reported results 2007-003158-27 A randomised, double-blind, parallel groups, placebo-controlled, multi-centre study assessing the effects of a selective oxytocin antagonist (barusiban) and a mixed oxytocin antagonist – vasopressin V... 2008-09-11 due-trials
Reported results 2007-003578-24 A single-centre, open-label, randomised explorative pharmacokinetic/pharmacodynamic study of the gonadotropin-releasing hormone receptor antagonist degarelix (FE 200486) in patients with benign prosta... 2009-03-23 due-trials
Reported results Terminated 2007-003735-23 A prospective, randomised study comparing a 3-sachet Picolax® treatment with the standard 2-sachet Picolax® for bowel cleansing prior to colonoscopy. 2010-12-23 due-trials
Reported results 2007-006055-39 An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen A... 2008-05-15 due-trials
Reported results 2008-000045-59 Multicentre, controlled, randomized, investigator-blinded, comparative study of oral Mesalazine 4g per day Once daily versus 4g per day in Two divided doses in patients with active Ulcerative coliti... 2010-06-16 due-trials
Reported results 2008-000585-22 An Open-Label, Multi-Centre, Uncontrolled, Exploratory Study, Investigating Degarelix One-Month Dosing Regimen as Second-Line Hormonal Treatment after PSA-Failure in GnRH Agonist Treated Patients with... 2011-12-29 due-trials
Reported results 2008-002100-26 PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sachet 6 g/day (mesalazine, mesalamine) with placebo 2010-11-18 due-trials
Reported results 2008-003931-19 An Open-Label, Multi-Centre, Uncontrolled, Trial Investigating Degarelix One-Month Dosing Regimen Administered as Intermittent Androgen Deprivation (IAD) for One Cycle in Patients with Prostate Cancer... 2013-07-10 due-trials
Reported results 2008-004338-26 A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of reduction in International Prostate Symptom Score (IPSS)... 2010-03-03 due-trials
Reported results 2008-004849-28 A randomised, open-label, parallel-group, multi-centre trial comparing the efficacy and safety of 12 months treatment with one daily dose of ZOMACTON® to one daily dose of GENOTROPIN® in the treatment... 2012-06-25 due-trials
Reported results 2008-005232-33 A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients of i... 2011-09-26 due-trials
Reported results 2008-005276-27 An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer ... 2011-03-03 due-trials
Reported results 2008-006775-67 A randomised, open-label, assessor-blind, parallel groups, multicentre trial comparing the efficacy of MENOPUR versus recombinant FSH in controlled ovarian stimulation following a GnRH antagonist prot... 2011-11-01 due-trials
Reported results 2008-006827-29 A Phase 3b, Non-randomized, Open-label, Multi-Centre, Follow-on Safety Trial of Monthly Doses of Degarelix in Patients with Prostate Cancer 2011-11-29 due-trials
Reported results 2008-008604-40 A randomised, parallel-arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of volume reduction of the prostate in patients with prosta... 2011-03-03 due-trials
Reported results 2009-010798-19 A randomized, double-blind, placebo-controlled, infusion proof-of-concept trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of FE 202158 in patien... 2011-09-14 due-trials
Reported results 2009-012323-29 A randomised, double-blind, parallel groups, placebo-controlled, multi-centre trial in oocyte donors assessing the effects of barusiban, a selective oxytocin antagonist, on uterine contractions on the... 2010-12-02 due-trials
Reported results 2009-012325-11 A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated wi... 2011-03-28 due-trials
Reported results 2010-019411-37 A Prospective, Open Label, Randomised, Parallel Group Trial Comparing the Effects of Highly Purified Menotrophin and Recombinant Follicle Stimulating Hormone (rFSH, Follitropin alpha) Administered Sub... 2013-01-22 due-trials
Reported results 2010-021434-55 An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androg... 2011-10-17 due-trials
Reported results 2011-000633-36 A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoing ... 2013-03-25 due-trials
Reported results 2012-001254-26 An open label feasibility trial investigating FE 202158 as potential primary vasopressor treatment in patients with vasodilatory hypotension in early septic shock 2013-11-15 due-trials
Reported results 2012-001622-10 A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation a... 2015-04-28 due-trials
Reported results Terminated 2012-004388-34 A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated with Desmopressin Orally Disintegrating Tablets as compared to Place... 2014-06-20 due-trials
Reported results 2012-005587-94 A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks 2015-06-01 due-trials
Reported results 2012-005588-28 A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed... 2014-05-03 due-trials
Reported results 2012-005601-46 A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation 2015-05-13 due-trials
Reported results 2013-001616-30 A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an a... 2017-01-03 due-trials
Reported results 2013-001669-17 A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the efficacy and safety of FE 999049 with follitropin alfa (GONAL-F) in controlled ovarian stimula... 2017-01-03 due-trials
Reported results 2014-000627-24 A follow-up study to examine the presence of anti-human growth hormone antibodies following a randomised, open-label, parallel-group, multi-centre trial (FE 999905 CS07) in which the efficacy and safe... 2015-08-17 due-trials
Reported results 2014-001062-10 A randomised, assessor-blinded, multi-centre trial comparing the efficacy, safety and tolerability of the PICOPREP tailored dosing schedule to the PICOPREP day-before dosing schedule for colon cleansi... 2015-06-08 due-trials
Reported results 2014-003973-41 A Double-blind, Randomised, Placebo-controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients with Vasopressor-dependent Septic Shoc... 2018-02-26 due-trials
Reported results 2015-000357-20 A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients with Prostate Cancer 2017-06-22 due-trials
Reported results 2015-002557-35 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopi... 2018-04-03 due-trials
Reported results 2015-002558-11 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic ... 2018-09-19 due-trials
Reported results 2016-003851-31 A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, with Desmopressin Orally Disintegra... 2019-10-31 due-trials
Reported results 2017-000808-22 An Open-label Trial Investigating the Association Between Nocturia and Sleep During 12 Weeks of Treatment with Desmopressin Orally Disintegrating Tablet (ODT) for Nocturia due to Nocturnal Polyuria in... 2018-07-13 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-002495-20 A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receivi... 2021-03-29 bad-data
Reported results 2017-002783-40 A randomised, controlled, open label, parallel group, multicentre trial comparing the efficacy and safety of individualised FE 999049 (follitropin delta) dosing, using a long GnRH agonist protocol a... 2022-09-27 due-trials
Listed as ongoing, but also has a completion date and reported results 2017-003810-13 A randomised, double-blind, placebo-controlled, parallel-group, dose-range trial to investigate the efficacy and safety of FE 999302 as add-on treatment to follitropin delta (REKOVELLE) in women under... 2021-09-13 bad-data
Reported results 2018-000915-26 A randomised, double-blind, placebo-controlled, proof-of-mechanism phase 2 trial investigating the effect of quinagolide extended-release vaginal ring on reduction of lesions assessed by high-resoluti... 2021-07-18 due-trials
Ongoing 2021-001785-38 A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response of a starting dose of 15 µg follitropin delta (REKOVELLE) to a starting dose ... not-yet-due
Other 2021-004254-37 A randomised, double-blind, placebo-controlled trial to assess the efficacy and safety of FE 999049 for treatment of men with idiopathic infertility not-yet-due
Reported results 2022-000753-80 A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women undergoin... 2022-12-13 due-trials